Changes in the risk of death after HIV seroconversion compared with mortality in the general population

被引:339
作者
Bhaskaran, Krishnan [1 ]
Hamouda, Osamah [2 ]
Sannes, Mette [3 ]
Boufassa, Faroudy [4 ]
Johnson, Anne M. [5 ]
Lambert, Paul C. [6 ]
Porter, Kholoud [1 ]
机构
[1] MRC, Clin Trials Unit, London NW1 2DA, England
[2] Robert Koch Inst, D-1000 Berlin, Germany
[3] Ullevaal Univ Hosp, Oslo, Norway
[4] Hop Bicetre, INSERM, U822, Paris, France
[5] UCL, London, England
[6] Univ Leicester, Leicester, Leics, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2008年 / 300卷 / 01期
基金
英国医学研究理事会;
关键词
D O I
10.1001/jama.300.1.51
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Mortality among human immunodeficiency virus ( HIV) - infected individuals has decreased dramatically in countries with good access to treatment and may now be close to mortality in the general uninfected population. Objective To evaluate changes in the mortality gap between HIV- infected individuals and the general uninfected population. Design, Setting, and Population Mortality following HIV seroconversion in a large multinational collaboration of HIV seroconverter cohorts ( CASCADE) was compared with expected mortality, calculated by applying general population death rates matched on demographic factors. A Poisson- based model adjusted for duration of infection was constructed to assess changes over calendar time in the excess mortality among HIV-infected individuals. Data pooled in September 2007 were analyzed in March 2008, covering years at risk 1981- 2006. Main Outcome Measure Excess mortality among HIV- infected individuals compared with that of the general uninfected population. Results Of 16 534 individuals with median duration of follow- up of 6.3 years ( range, 1 day to 23.8 years), 2571 died, compared with 235 deaths expected in an equivalent general population cohort. The excess mortality rate ( per 1000 person- years) decreased from 40.8 ( 95% confidence interval [ CI], 38.5- 43.0; 1275.9 excess deaths in 31 302 person- years) before the introduction of highly active antiretroviral therapy ( pre- 1996) to 6.1 ( 95% CI, 4.8- 7.4; 89.6 excess deaths in 14 703 person- years) in 2004- 2006 ( adjusted excess hazard ratio, 0.05 [ 95% CI, 0.03- 0.09] for 2004- 2006 vs pre- 1996). By 2004- 2006, no excess mortality was observed in the first 5 years following HIV seroconversion among those infected sexually, though a cumulative excess probability of death remained over the longer term ( 4.8% [ 95% CI, 2.5%- 8.6%] in the first 10 years among those aged 15- 24 years). Conclusions Mortality rates for HIV- infected persons have become much closer to general mortality rates since the introduction of highly active antiretroviral therapy. In industrialized countries, persons infected sexually with HIV now appear to experience mortality rates similar to those of the general population in the first 5 years following infection, though a mortality excess remains as duration of HIV infection lengthens.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 29 条
[1]  
[Anonymous], 1958, Journal of Chronic Disease
[2]   Long-term cancer patient survival achieved by the end of the 20th century: most up-to-date estimates from the nationwide Finnish cancer registry [J].
Brenner, H ;
Hakulinen, T .
BRITISH JOURNAL OF CANCER, 2001, 85 (03) :367-371
[3]   The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis [J].
Capocaccia, R. ;
Gatta, G. ;
Roazzi, P. ;
Carrani, E. ;
Santaquilani, M. ;
De Angelis, R. ;
Tavilla, A. .
ANNALS OF ONCOLOGY, 2003, 14 :V14-V27
[4]   Substance abuse and psychiatric disorders in HIV-positive patients - Epidemiology and impact on antiretroviral therapy [J].
Chander, Geetanjali ;
Himelhoch, Seth ;
Moore, Richard D. .
DRUGS, 2006, 66 (06) :769-789
[5]   Variation in relative survival of thyroid cancers in Europe:: Results from the analysis on 21 countries over the period 1983-1994 (EUROCARE-3 study) [J].
Colonna, Marc ;
Grande, Enrico ;
Jonasson, Jon G. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) :2598-2608
[6]   Regression models for relative survival [J].
Dickman, PW ;
Sloggett, A ;
Hills, M ;
Hakulinen, T .
STATISTICS IN MEDICINE, 2004, 23 (01) :51-64
[7]  
Ederer F, 1959, 10 NCI END RES EV SE
[8]  
EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101
[9]   Survival following HIV infection of a cohort followed up from seroconversion in the UK [J].
Ewings, Fiona M. ;
Bhaskaran, Krishnan ;
McLean, Ken ;
Hawkins, David ;
Fisher, Martin ;
Fidler, Sarah ;
Gilson, Richard ;
Nock, Demelza ;
Brettle, Ray ;
Johnson, Margaret ;
Phillips, Andrew ;
Porter, Kholoud .
AIDS, 2008, 22 (01) :89-95
[10]   Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study [J].
Friis-Moller, N ;
Weber, R ;
Reiss, P ;
Thiébaut, R ;
Kirk, O ;
Monforte, AD ;
Pradier, C ;
Morfeldt, L ;
Mateu, S ;
Law, M ;
El-Sadr, W ;
De Wit, S ;
Sabin, CA ;
Phillips, AN ;
Lundgren, JD .
AIDS, 2003, 17 (08) :1179-1193